Experimental Malaria Vaccine

Experimental Malaria Vaccine, Scientists say they are about to have the vaccine against malaria in the world first. The results of a major clinical trial, published Tuesday in The New England Journal of Medicine website, shows an experimental vaccine against malaria by half the risk of African children against malaria.

The trial, conducted in 11 trial sites in seven countries in Africa, showed three doses of RTS, S reduced the risk of children suffering from clinical malaria and severe malaria by 56% and 47% respectively. The clinical outcomes of malaria in high fever and chills and may develop rapidly in severe malaria, characterized by severe effects on blood, brain or kidneys that can be fatal.

The researchers hope that RTS, S could be released in 2015.

GlaxoSmithKline paid for the study along with the PATH Malaria Vaccine Initiative, a program funded by the Bill & Melinda Gates Foundation,